Cardioprotective effect of sevoflurane and propofol during anaesthesia and the postoperative period in coronary bypass graft surgery: A double-blind randomised study

European Journal of Anaesthesiology

Volumn 29, Issue 12, 2012, Pages 561-569

  Soro, Marina ^a   Gallego, Lucía ^a   Silva, Vanessa ^a   Ballester, María T ^a   Lloréns, Julio ^a   Alvariño, Ana ^a   García Perez, María L ^a   Pastor, Ernesto ^a   Aguilar, Gerardo ^a   Martí, Francisco J ^a,b   Carratala, Arturo ^a   Belda, F Javier ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Biological markers; Coronary artery bypass; Heart drug effects; Methyl ethers pharmacology; Propofol pharmacology

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; CREATINE KINASE MB; MYOGLOBIN; PROPOFOL; SEVOFLURANE; TROPONIN I;

AGED; ANESTHESIA; ARTICLE; ARTIFICIAL VENTILATION; CENTRAL VENOUS PRESSURE; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DOUBLE BLIND PROCEDURE; FEMALE; HEART ARRHYTHMIA; HEART HEMODYNAMICS; HEART INDEX; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; HEART STROKE VOLUME; HUMAN; INCIDENCE; INOTROPISM; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; POSTOPERATIVE CARE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEDATION; SURGICAL PATIENT; SYSTEMIC VASCULAR RESISTANCE;

AGED; ANESTHESIA; ANESTHETICS, INHALATION; BIOLOGICAL MARKERS; CARDIAC SURGICAL PROCEDURES; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; FEMALE; HEART; HEMODYNAMICS; HUMANS; INTENSIVE CARE; ISCHEMIC PRECONDITIONING; MALE; METHYL ETHERS; MIDDLE AGED; MYOCARDIUM; POSTOPERATIVE PERIOD; PROPOFOL; PROSPECTIVE STUDIES; RESPIRATION, ARTIFICIAL; TIME FACTORS;

EID: 84872251757     PISSN: 02650215     EISSN: 13652346     Source Type: Journal    
DOI: 10.1097/EJA.0b013e3283560aea     Document Type: Article

References (79)

1. Obal D, Dettwiler S, Favoccia C, et al. The influence of mitochondrial KATP- channels in the cardioprotection of preconditioning and postconditioning by sevoflurane in the rat in vivo. Anesth Analg 2005; 101:1252-1260.
2. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: underlying mechanisms and clinical application. Atherosclerosis 2009; 204:334-341.
3. Wang C, Neff DA, Krolikowski JG, et al. The influence of B-cell lymphoma 2 protein, an antiapoptotic regulator of mitochondrial permeability transition, on isoflurane-induced and ischemic postconditioning in rabbits. Anesth Analg 2006; 102:1355-1360.
4. Sasaki H, Shimizu M, Ogawa K, et al. Brief ischemia-reperfusion performed after prolonged ischemia (ischemic postconditioning) can terminate reperfusion arrhythmias with no reduction of cardiac function in rats. Int Heart J 2007; 48:205-213.
5. Conzen PF, Fisher S, Detter C, Peter K. Sevoflurane provides greater protection of the myocardium than propofol in patients undergoing off-pump coronary artery bypass surgery. Anesthesiology 2003; 99:826-833.
6. Bein B, Renner J, Caliebe D, et al. Sevoflurane but not propofol preserves myocardial function during minimally invasive direct coronary artery bypass surgery. Anesth Analg 2005; 100:610-616.
7. Guarracino F, Landoni G, Tritapepe L, et al. Myocardial damage prevented by volatile anesthetics: a multicenter randomised controlled study. J Cardiothorac Vasc Anesth 2006; 20:477-483.
8. Kawamura T, Kadosaki M, Nara N, et al. Effects of sevoflurane on cytokine balance in patients undergoing coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2006; 20:503-508.
9. Tritapepe L, Landoni G, Guarracino F, et al. Cardiac protection by volatile anaesthetics: a multicentre randomized controlled study in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Eur J Anaesthesiol 2007; 24:323-331.
10. Lucchinetti E, Hofer C, Bestmann L, et al. Gene regulatory control of myocardial energy metabolism predicts postoperative cardiac function in patients undergoing off-pump coronary artery bypass graft surgery. Anesthesiology 2007; 106:444-457.
11. Tanaka K, Ludwig LM, Kersten JR, et al. Mechanisms of cardioprotection by volatile anesthetics. Anesthesiology 2004; 100:707-721.
12. Yu CH, Beattie WS. The effects of volatile anesthetics on cardiac ischemic complications and mortality in CABG: a meta-analysis. Can J Anaesth 2006; 53:906-918.
13. Symons JA, Myles PS. Myocardial protection with volatile anaesthetic agents during coronary artery bypass surgery: a meta-analysis. Br J Anaesth 2006; 97:127-136.
14. Landoni G, Biondi-Zoccai GG, Zangrillo A, et al. Desflurane and sevoflurane in cardiac surgery: a meta-analysis of randomized clinical trials. J Cardiothorac Vasc Anesth 2007; 21:502-511.
15. De Hert SG, van der Linden PJ, Cromheecke S, et al. Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration. Anesthesiology 2004; 101:299-310.
16. De Hert SG, ten Broecke PW, Mertens E, et al. Sevoflurane but not propofol preserves myocardial function in coronary surgery patients. Anesthesiology 2002; 97:42-49.
17. De Hert SG, Cromheecke S, ten Broecke PW, et al. Effects of propofol, desflurane, and sevoflurane on recovery of myocardial function after coronary surgery in elderly high-risk patients. Anesthesiology 2003; 99:314- 323.
18. De Hert SG, van der Linden PJ, Cromheecke S, et al. Choice of primary anesthetic regimen can influence intensive care unit length of stay after coronary surgery with cardiopulmonary bypass. Anesthesiology 2004; 101:9-20.
19. Garcia C, Julier K, Bestmann L, et al. Preconditioning with sevoflurane decreases PECAM-1 expression and improves one-year cardiovascular outcome in coronary artery bypass graft surgery. Br J Anaesth 2005; 94:159-165.
20. De Hert H, Vlasselaers D, Barbé R, et al. A comparison of volatile and nonvolatile agents for cardioprotection during on-pump coronary surgery. Anaesthesia 2009; 64:953-960.
21. Frässdorf J, Borowski A, Ebel D, et al. Impact of preconditioning protocol on anesthetic-induced cardioprotection in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2009; 137:1436- 1442.
22. Bein B, Renner J, Caliebe D, et al. The effects of interrupted or continuous administration of sevoflurane on preconditioning before cardiopulmonary bypass in coronary artery surgery: comparison with continuous propofol. Anaesthesia 2008; 63:1046-1055.
23. Pagel PS. Postconditioning by volatile anesthetics: salvaging ischemic myocardium at reperfusion by activation of prosurvival signaling. J Cardiothorac Vasc Anesth 2008; 22:753-765.
24. Opie LH, Lecour S. Delayed postconditioning: cardioprotection at the limit? Circulation 2011; 124:1315-1318.
25. Millane TA, Bennett ED, Grounds RM. Isoflurane and propofol for long-term sedation in the intensive care unit. A crossover study. Anaesthesia 1992; 47:768-774.
26. Kong KL, Willatts SM, Prys-Roberts C. Isoflurane compared with midazolam for sedation in the intensive care unit. BMJ 1989; 298:1277- 1280.
27. Spencer EM, Willatts SM. Isoflurane for prolonged sedation in the intensive care unit; efficacy and safety. Intensive Care Med 1992; 18:415-421.
28. Halpenny D. Sevoflurane sedation. Can J Anaesth 2000; 47:193-194.
29. Ibrahim AE, Ghoneim MM, Kharasch ED, et al. Sevoflurane Sedation Study Group. Speed of recovery and side-effect profile of sevoflurane sedation compared with midazolam. Anesthesiology 2001; 94:87-94.
30. Meiser A, Sirtl C, Bellgardt M, et al. Desflurane compared with propofol for postoperative sedation in the intensive care unit. Br J Anaesth 2003; 90:273-280.
31. Wild MR, Gornall CB, Griffiths DE, Curran J. Maintenance of anaesthesia with sevoflurane or isoflurane effects on adverse airway events in smokers. Anaesthesia 2004; 59:891-893.
32. [German guidelines for the management of analgesia, sedation and delirium in intensive care. Association of Scientific Medical Societies (AWMF) of Germany]. http://www.un-duesseldorf.de/AWMF/ll/001- 012m.html. [Accessed 12 January 2012].
33. Enlund M, Wiklund L, Lambert H. A new device to reduce the consumption of a halogenated anaesthetic agent. Anaesthesia 2001; 56:429-432.
34. Enlund M, Lambert H, Wiklund L. The sevoflurane saving capacity of a new anaesthetic agent conserving device compared with a low flow circle system. Acta Anaesthesiol Scand 2002; 46:506-511.
35. Tempia A, Olivei MC, Calza E, et al. The anesthetic conserving device compared with conventional circle system used under different flow conditions for inhaled anesthesia. Anesth Analg 2003; 96:1056- 1061.
36. Belda FJ, Soro M, Badenes R, et al. The predictive performance of a pharmacokinetic model for manually adjusted infusion of liquid sevoflurane for use with the Anesthetic-Conserving Device (AnaConDa): a clinical study. Anesth Analg 2008; 106:1207-1214.
37. Domanski MJ, Mahaffey K, Hasselblad V, et al. Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA 2011; 305:585-591.
38. Julier K, Da Silva R, Garci'a G, et al. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study. Anesthesiology 2003; 98:1315-1327.
39. Chello M, Mastroroberto P, Perdicone F, et al. Plasma levels of atrial and brain natriuretic peptides as indicators of recovery of left ventricular systolic function after coronary artery bypass. Eur J Cardiothoracic Surg 2001; 20:140-146.
40. Sabatine MS, Morrow DA, De Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes. Simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002; 105:1760-1763.
41. Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Circulation 2007; 116:2634-2653.
42. Frässdorf J, De Hert S, Schlack W. Anaesthesia and myocardial ischaemia/reperfusion injury. Br J Anaesth 2009; 103:89-98.
43. Yao YT, Li LH, Chen L, et al. Sevoflurane postconditioning protects isolated rat hearts against ischemia-reperfusion injury: the role of radical oxygen species, extracellular signal-related kinases 1/2 and mitochondrial permeability transition pore. Mol Biol Rep 2009; 37:2439-2446.
44. Yao Y, Li L, Gao C, Shi C. Sevoflurane postconditioning protects chronically-infarcted rat hearts against ischemia-reperfusion injury by activation of pro-survival kinases and inhibition of mitochondrial permeability transition pore opening upon reperfusion. Biol Pharm Bull 2009; 32:1854-1861.
45. Hausenloy DJ, Ong SB, Yellon DM. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol 2009; 104:189-202.
46. Van der Linden PJ, Daper A, de Hert SG. Cardioprotective effects of volatile anesthetics in cardiac surgery. Anesthesiology 2003; 99:516-517.
47. Belhomme D, Peynet J, Louzy M, et al. Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery. Circulation 1999; 100:340-344.
48. Penta de Peppo A, Polisca P, et al. Recovery of LV contractility in man is enhanced by preischemic administration of enflurane. Ann Thorac Surg 1999; 68:112-118.
49. Tomai F, De Paulis R, Penta de Peppo A, et al. Beneficial impact of isoflurane during coronary bypass surgery on troponin I release. G Ital Cardiol 1999; 29:1007-1014.
50. Haroun-Bizri S, Khoury SS, Chehab IR, et al. Does isoflurane optimize myocardial protection during cardiopulmonary bypass? J Cardiothorac Vasc Anesth 2001; 15:418-421.
51. Lee MC, Chen CH, Kuo MC, et al. Isoflurane preconditioning-induced cardioprotection in patients undergoing coronary artery bypass grafting. Eur J Anaesthesiol 2006; 23:841-847.
52. Meco M, Cirri S, Gallazzi C, et al. Desflurane preconditioning in coronary artery bypass graft surgery: a double-blinded, randomised and placebo controlled study. Eur J Cardiothorac Surg 2007; 32:319-325.
53. Ndoko SK, Tual L, Ait Mamar B, et al. Isoflurane 0.5 minimum alveolar concentration administered through the precardiopulmonary bypass period reduces postoperative dobutamine requirements of cardiac surgery patients: a randomized study. J Cardiothorac Vasc Anesth 2007; 21:683-689.
54. Pouzet B, Lecharny JB, Dehoux M, et al. Is there a place for preconditioning during cardiac operations in humans? Ann Thorac Surg 2002; 73:843-848.
55. Fellahi JL, Gue X, Philippe E, et al. Isoflurane may not influence postoperative cardiac troponin I release and clinical outcome in adult cardiac surgery. Eur J Anaesthesiol 2004; 21:688-693.
56. Piriou V, Mantz J, Goldfarb G, et al. Sevoflurane preconditioning at 1 MAC only provides limited protection in patients undergoing coronary artery bypass surgery: a randomized bi-centre trial. Br J Anaesth 2007; 99:624-631.
57. Botha P, Nagarajan DV, Lewis PS, Dunning J. Can cardiac troponins be used to diagnose a perioperative myocardial infarction post cardiac surgery? Interact Cardiovasc Thorac Surg 2004; 3:442-449.
58. Nader ND, Li CM, Khadra WZ, et al. Anesthetic myocardial protection with sevoflurane. J Cardiothorac Vasc Anesth 2004; 18:269-274.
59. Weber NC, Preckel B, Schlack W. The effect of anaesthetics on the myocardium: new insights into myocardial protection. Eur J Anaesthesiol 2005; 22:647-657.
60. Bignami E, Landoni G, Gerli C, et al. Sevoflurane vs. propofol in patients with coronary disease undergoing mitral surgery: a randomised study. Acta Anaesthesiol Scand. 2011. doi: 10.1111/j.1399-6576.2011.02570.x. [Epub ahead of print]
61. Yao Y-T, Li L-H. Sevoflurane versus propofol for myocardial protection in patients undergoing coronary artery bypass grafting surgery: a meta-analysis of randomized controlled trials. Chin Med Sci J 2009; 24:133-141.
62. Jakobsen CJ, Berg H, Hindsholm KB, et al. The influence of propofol versus sevoflurane anesthesia on outcome in 10 535 cardiac surgical procedures. J Cardiothorac Vasc Anesth 2007; 21:664-671.
63. Landoni G, Augoustides JG, Guarracino F, et al. Mortality reduction in cardiac anesthesia and intensive care: results of the first International Consensus Conference. Acta Anaesthesiol Scand 2011; 55:259-266.
64. Landoni G, Fochi O, Tritapepe L, et al. Cardiac protection by volatile anesthetics. A review. Minerva Anestesiol 2009; 75:269-273.
65. Ye Y, Perez-Polo JR, Aguilar D, Birnbaum Y. The potential effects of antidiabetic medications on myocardial ischemia-reperfusion injury. Basic Res Cardiol 2011; 106:925-952.
66. Zaugg M. Is protection by inhalation agents volatile? Controversies in cardioprotection. Br J Anaesth 2007; 99:603-606.
67. Mio Y, Bienengraeber MW, Marinovic J, et al. Age-related attenuation of isoflurane preconditioning in human atrial cardiomyocytes: roles for mitochondrial respiration and sarcolemmal adenosine triphosphatesensitive potassium channel activity. Anesthesiology 2008; 108:612-620.
68. Wang C, Chiari PC, Weihrauch D, et al. Gender-specificity of delayed preconditioning by isoflurane in rabbits: potential role of endothelial nitric oxide synthase. Anesth Analg 2006; 103:274-280.
69. Preckel B, Weber NC, Sanders RD, et al. Molecular mechanisms transducing the anesthetic, analgesic, and organ protective actions of xenon. Anesthesiology 2006; 105:187-197.
70. Siracusano L, Girasole V. Sevoflurane and cardioprotection. Br J Anaesth 2008; 100:278; author reply 278-279.
71. Lucchinetti E, Ambrosio S, Aguirre J, et al. Sevoflurane inhalation at sedative concentrations provides endothelial protection against ischemia- reperfusion injury in humans. Anesthesiology 2007; 106:262-268.
72. Deyhimy DI, Fleming NW, Brodkin IG, Liu H. Anesthetic preconditioning combined with postconditioning offers no additional benefit over preconditioning or postconditioning alone. Anesth Analg 2007; 105:316- 324.
73. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007; 59:418-458.
74. Gross GJ. Role of opioids in acute and delayed preconditioning. J Mol Cell Cardiol 2003; 35:709-718.
75. Peart JN, Gross ER, Gross GJ. Opioid-induced preconditioning: recent advances and future perspectives. Vascul Pharmacol 2005; 42:211-218.
76. Schultz JE, Gross GJ. Opioids and cardioprotection. Pharmacol Ther 2001; 89:123-137.
77. Law-Koune JD, Raynaud C, Liu N, et al. Sevoflurane-remifentanil versus propofol-remifentanil anesthesia at a similar bispectral level for off-pump coronary artery surgery: no evidence of reduced myocardial ischemia. J Cardiothorac Vasc Anesth 2006; 20:484-492.
78. Hellström J, Öwall A, Bergström J, Sackey PV. Cardiac outcome after sevoflurane versus propofol sedation following coronary bypass surgery: a pilot study. Acta Anaesthesiol Scand 2011; 55:460-467.
79. Lucchinetti E, Bestmann L, Feng J, et al. Remote ischemic preconditioning applied during isoflurane inhalation provides no benefit to the myocardium of patients undergoing on-pump coronary artery bypass graft surgery: lack of synergy or evidence of antagonism in cardioprotection? Anesthesiology 2012; 116:296-310.